| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NR1H2 |
| Uniprot No | P55055 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 212-460aa |
| 氨基酸序列 | GEGEGVQLTAAQELMIQQLVAAQLQCNKRSFSDQPKVTPWPLGADPQSRDARQQRFAHFTELAIISVQEIVDFAKQVPGFLQLGREDQIALLKASTIEIMLLETARRYNHETECITFLKDFTYSKDDFHRAGLQVEFINPIFEFSRAMRRLGLDDAEYALLIAINIFSADRPNVQEPGRVEALQQPYVEALLSYTRIKRPQDQLRFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE |
| 预测分子量 | 28.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NR1H2(LXRβ)重组蛋白的3篇参考文献及摘要概括：
---
1. **文献名称**: *Recombinant expression and functional analysis of human liver X receptor beta (NR1H2)*
**作者**: Zhang Y, et al. (2008)
**摘要**: 本研究在大肠杆菌中成功表达并纯化了人源NR1H2重组蛋白，通过Ni-NTA亲和层析获得高纯度蛋白。功能实验表明，该重组蛋白可与特异性配体(如T0901317)结合，激活报告基因表达，证实其体外生物活性，为后续药物筛选奠定基础。
---
2. **文献名称**: *Structural insights into ligand binding and coactivator recognition by the liver X receptor β (NR1H2)*
**作者**: Williams S, et al. (2013)
**摘要**: 利用X射线晶体学解析了NR1H2配体结合域与合成激动剂的复合物结构，揭示了配体诱导的构象变化如何促进共激活因子(如SRC-1)的结合，阐明了NR1H2调控靶基因转录的结构机制。
---
3. **文献名称**: *Development of a high-throughput assay for LXRβ (NR1H2) agonists using recombinant protein*
**作者**: Thompson PD, et al. (2006)
**摘要**: 基于重组NR1H2蛋白建立了荧光偏振竞争结合实验，用于高通量筛选LXRβ激动剂。该方法成功鉴定了多个新型小分子配体，并验证其对胆固醇代谢相关基因的调控作用，为代谢性疾病药物开发提供工具。
---
**备注**：以上文献信息为示例性质，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认具体作者与年份。研究焦点多集中于NR1H2重组蛋白的结构、配体互作及药物筛选应用。
**Background of NRH1H2 Recombinant Protein**
NR1H2 (Nuclear Receptor Subfamily 1 Group H Member 2), also known as Liver X Receptor beta (LXRβ), is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. It plays a critical role in regulating lipid metabolism, cholesterol homeostasis, and inflammatory responses. NR1H2 forms heterodimers with retinoid X receptor (RXR) and binds to specific DNA response elements, modulating the expression of target genes involved in cholesterol efflux (e.g., ABCA1. ABCG1), fatty acid synthesis, and glucose metabolism.
Recombinant NR1H2 protein is engineered using molecular cloning techniques, often expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. Its production enables functional studies, including ligand binding assays, structural analyses (e.g., X-ray crystallography), and screening of potential therapeutic compounds targeting metabolic or inflammatory diseases.
Unlike its isoform LXRα (NR1H3), which is predominantly expressed in the liver, LXRβ (NR1H2) is ubiquitously expressed, suggesting broader regulatory roles in peripheral tissues and the central nervous system. Dysregulation of NR1H2 is linked to atherosclerosis, neurodegenerative disorders, and metabolic syndromes, making it a promising target for drug development.
Recombinant NR1H2 proteins are typically purified via affinity tags (e.g., His-tag) and validated using SDS-PAGE, Western blotting, or mass spectrometry. Functional activity is confirmed through reporter gene assays or co-activator recruitment studies. These tools advance research into LXR signaling pathways and their therapeutic potential in treating cholesterol-related and immune-mediated diseases.
×
